$EVFM
Evofem Biosciences, Inc. Stock $evfm

$evfm Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000149315224046060 Filed on November 14, 2024

Income Statement

Concept	2024 Q4	2024 Q3	2023 Q3
Revenue		$4.496M	$5.112M
YoY Change		-12.05%	-19.76%
Cost Of Revenue		$869.0K	$1.889M
YoY Change		-54.0%	12.44%
Gross Profit		$3.627M	$3.223M
YoY Change		12.53%	-31.29%
Gross Profit Margin		80.67%	63.05%
Selling, General & Admin		$5.434M	$6.161M
YoY Change		-11.8%	-66.16%
% of Gross Profit		149.82%	191.16%
Research & Development		$332.0K	$614.0K
YoY Change		-45.93%	-88.21%
% of Gross Profit		9.15%	19.05%
Depreciation & Amortization			$37.00K
YoY Change			-85.2%
% of Gross Profit			1.15%
Operating Expenses		$5.766M	$6.775M
YoY Change		-14.89%	-71.07%
Operating Profit		-$2.440M	-$3.552M
YoY Change		-31.31%	-81.03%
Interest Expense			-$5.173M
YoY Change			-104.76%
% of Operating Profit
Other Income/Expense, Net		$67.00K	$69.57M
YoY Change		-99.9%	-35.73%
Pretax Income		-$2.373M	$66.02M
YoY Change		-103.59%	-26.25%
Income Tax		-$8.000K	$11.00K
% Of Pretax Income			0.02%
Net Earnings		-$2.365M	$66.01M
YoY Change		-103.58%	-26.26%
Net Earnings / Revenue		-52.6%	1291.18%
Basic Earnings Per Share		-$0.02	$15.34
Diluted Earnings Per Share		-$0.02	$0.10
COMMON SHARES
Basic Shares Outstanding	100.3M shares	100.3M shares	4.060M shares
Diluted Shares Outstanding		96.46M shares	730.0M shares

Balance Sheet

Concept	2024 Q3	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments		$0.00
YoY Change		-100.0%
Cash & Equivalents
Short-Term Investments
Other Short-Term Assets		$2.657M
YoY Change		-56.45%
Inventory	$1.463M	$2.526M
Prepaid Expenses
Receivables	$5.393M	$6.322M
Other Receivables		$0.00
Total Short-Term Assets	$8.577M	$11.51M
YoY Change	-25.45%	-63.81%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.181M	$1.631M
YoY Change	-27.59%	-61.86%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$36.00K	$35.00K
YoY Change	2.86%	-96.85%
Total Long-Term Assets	$15.37M	$1.817M
YoY Change	745.62%	-82.68%
TOTAL ASSETS
Total Short-Term Assets	$8.577M	$11.51M
Total Long-Term Assets	$15.37M	$1.817M
Total Assets	$23.94M	$13.32M
YoY Change	79.72%	-68.49%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$16.86M	$16.20M
YoY Change	4.11%	11.39%
Accrued Expenses	$5.124M	$5.100M
YoY Change	0.47%	-7.36%
Deferred Revenue	$4.500M
YoY Change
Short-Term Debt	$268.0K	$0.00
YoY Change
Long-Term Debt Due		$41.08M
YoY Change		-47.01%
Total Short-Term Liabilities	$76.29M	$67.87M
YoY Change	12.4%	-41.85%
LONG-TERM LIABILITIES
Long-Term Debt		$0.00
YoY Change
Other Long-Term Liabilities		$12.43K
YoY Change
Total Long-Term Liabilities		$12.43K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$76.29M	$67.87M
Total Long-Term Liabilities		$12.43K
Total Liabilities	$90.07M	$67.88M
YoY Change	32.69%	-43.59%
SHAREHOLDERS EQUITY
Retained Earnings	-$894.6M	-$884.6M
YoY Change	1.13%	-4.92%
Common Stock	$10.00K	$0.00
YoY Change		-100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$70.89M	-$56.36M
YoY Change
Total Liabilities & Shareholders Equity	$23.94M	$13.32M
YoY Change	79.72%	-68.49%

Cashflow Statement

Concept	2024 Q3	2023 Q3
OPERATING ACTIVITIES
Net Income	-$2.365M	$66.01M
YoY Change	-103.58%	-26.26%
Depreciation, Depletion And Amortization		$37.00K
YoY Change		-85.2%
Cash From Operating Activities		-$2.364M
YoY Change		-85.5%
INVESTING ACTIVITIES
Capital Expenditures		$0.00
YoY Change		-100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities		$0.00
YoY Change		-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		2.138M
YoY Change		-45.82%
NET CHANGE
Cash From Operating Activities		-2.364M
Cash From Investing Activities		0.000
Cash From Financing Activities		2.138M
Net Change In Cash		-226.0K
YoY Change		-98.18%
FREE CASH FLOW
Cash From Operating Activities		-$2.364M
Capital Expenditures		$0.00
Free Cash Flow		-$2.364M
YoY Change		-85.43%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5124000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4227000	usd
CY2024Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3222000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2609000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	116000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	97000	usd
CY2024Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	162000	usd
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	1926000	usd
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2024Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3000000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3000000000	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	100328686	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	100328686	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	20007799	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	20007799	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	10000	usd
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	825430000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	823036000	usd
CY2024Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1707000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-849000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-894621000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-888699000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	-70888000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-66510000	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	23942000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	10554000	usd
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4496000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5112000	usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001618835
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-36754
	dei	Entity Registrant Name EntityRegistrantName	EVOFEM BIOSCIENCES, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-8527075
	dei	Entity Address Address Line1 EntityAddressAddressLine1	7770 Regents Road
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 113-618
	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92122
	dei	City Area Code CityAreaCode	(858)
	dei	Local Phone Number LocalPhoneNumber	550-1900
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
	dei	Trading Symbol TradingSymbol	EVFM
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	722000	usd
CY2024Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5393000	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	1463000	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	999000	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	8577000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1181000	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	127000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue		usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet		usd
CY2023Q4	us-gaap	Short Term Borrowings ShortTermBorrowings		usd
CY2023Q4	EVFM	Contingent Liabilities Current ContingentLiabilitiesCurrent		usd
CY2023Q4	EVFM	Contingent Liabilities Noncurrent ContingentLiabilitiesNoncurrent		usd
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets		usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets		usd
CY2024Q3	us-gaap	Gain Loss On Sale Of Derivatives GainLossOnSaleOfDerivatives		usd
CY2023Q3	EVFM	Change In Fair Value Of Financial Instruments ChangeInFairValueOfFinancialInstruments		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q3	EVFM	Convertible Preferred Deemed Dividends ConvertiblePreferredDeemedDividends		usd
	EVFM	Convertible Preferred Deemed Dividends ConvertiblePreferredDeemedDividends		usd
CY2023Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues		usd
CY2023Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues		usd
CY2023Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
CY2023Q3	us-gaap	Warrant Down Round Feature Increase Decrease In Equity Amount1 WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1		usd
	us-gaap	Inventory Write Down InventoryWriteDown		usd
	EVFM	Loss On Contingent Liability LossOnContingentLiability		usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets		usd
	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease		usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired		usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock		usd
	EVFM	Proceeds From Reinstatement Of Merger Agreement Related Party ProceedsFromReinstatementOfMergerAgreementRelatedParty		usd
	EVFM	Exchange Of Convertible Notes To Series E1 Convertible Preferred Stock ExchangeOfConvertibleNotesToSeriesE1ConvertiblePreferredStock		usd
	EVFM	Borrowings Under Term Notes Included In Prepaid And Other Current Assets BorrowingsUnderTermNotesIncludedInPrepaidAndOtherCurrentAssets		usd
	EVFM	Net Change In Contingent Consideration Liabilities NetChangeInContingentConsiderationLiabilities		usd
	EVFM	Allocation Of Reinstatement Proceeds Related Party AllocationOfReinstatementProceedsRelatedParty		usd
	EVFM	Series E1 Shares Dividends SeriesE1SharesDividends		usd
	EVFM	Rightofuse Assets Obtained For Lease Liabilities Fleet Lease Renewals RightofuseAssetsObtainedForLeaseLiabilitiesFleetLeaseRenewals		usd
	EVFM	Acquisition Related Amounts Included In Accounts Payable And Accrued Expenses AcquisitionRelatedAmountsIncludedInAccountsPayableAndAccruedExpenses		usd
	EVFM	Issuance Of Common Stock Upon Conversion Of Notes IssuanceOfCommonStockUponConversionOfNotes		usd
	EVFM	Issuance Of Common Stock Upon Exercise Of Warrants IssuanceOfCommonStockUponExerciseOfWarrants		usd
	EVFM	Purchases Of Property And Equipment Included In Accounts Payable And Accrued Expenses PurchasesOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses		usd
CY2024Q3	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts		usd
CY2024Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization		usd
CY2024Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet		usd
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92122
	dei	Entity Listing Par Value Per Share EntityListingParValuePerShare	0.0001
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	100328686	shares
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	580000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5738000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	1697000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1195000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	9210000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1203000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	106000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	14021000	usd
CY2024Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	36000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	35000	usd
CY2024Q3	us-gaap	Assets Assets	23942000	usd
CY2023Q4	us-gaap	Assets Assets	10554000	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	16864000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	17020000	usd
CY2024Q3	us-gaap	Short Term Borrowings ShortTermBorrowings	268000	usd
CY2024Q3	EVFM	Contingent Liabilities Current ContingentLiabilitiesCurrent	808000	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	76286000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	72463000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	10000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8000	usd
CY2024Q3	EVFM	Contingent Liabilities Noncurrent ContingentLiabilitiesNoncurrent	13775000	usd
CY2024Q3	us-gaap	Liabilities Liabilities	90071000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	72471000	usd
CY2024Q3	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2024Q3	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	4759000	usd
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	4593000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	2000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	12259000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	13379000	usd
CY2024Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	869000	usd
CY2023Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1889000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2322000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5558000	usd
CY2024Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	301000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	301000	usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	332000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	614000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1196000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1556000	usd
CY2024Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2382000	usd
CY2023Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2985000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	6970000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	9036000	usd
CY2024Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3052000	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3176000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8143000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11696000	usd
CY2024Q3	us-gaap	Costs And Expenses CostsAndExpenses	6936000	usd
CY2023Q3	us-gaap	Costs And Expenses CostsAndExpenses	8664000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	18932000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	27846000	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2440000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3552000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-6673000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-14467000	usd
CY2024Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	3000	usd
CY2023Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	2000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	13000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	28000	usd
CY2024Q3	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	562000	usd
CY2023Q3	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	596000	usd
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	1736000	usd
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	2041000	usd
CY2023Q3	us-gaap	Gain Loss On Sale Of Derivatives GainLossOnSaleOfDerivatives	-5175000	usd
	us-gaap	Gain Loss On Sale Of Derivatives GainLossOnSaleOfDerivatives	-3300000	usd
	us-gaap	Gain Loss On Sale Of Derivatives GainLossOnSaleOfDerivatives	-5286000	usd
CY2024Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-143000	usd
CY2023Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	75337000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	977000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	75337000	usd
CY2024Q3	EVFM	Change In Fair Value Of Financial Instruments ChangeInFairValueOfFinancialInstruments	769000	usd
	EVFM	Change In Fair Value Of Financial Instruments ChangeInFairValueOfFinancialInstruments	4896000	usd
	EVFM	Change In Fair Value Of Financial Instruments ChangeInFairValueOfFinancialInstruments	1539000	usd
CY2024Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	67000	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	69568000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	850000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	69577000	usd
CY2024Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2373000	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	66016000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5823000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	55110000	usd
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-8000	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	11000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	17000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-2365000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	66005000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-5823000	usd
	us-gaap	Net Income Loss NetIncomeLoss	55093000	usd
CY2024Q3	EVFM	Convertible Preferred Deemed Dividends ConvertiblePreferredDeemedDividends	-5000	usd
	EVFM	Convertible Preferred Deemed Dividends ConvertiblePreferredDeemedDividends	-99000	usd
CY2024Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2370000	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	66005000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5922000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	55093000	usd
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	15.34
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.09
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	21.42
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.10
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.09
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.09
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	96459121	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4236477	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	64924454	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2524302	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	96459121	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	729979486	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	64924454	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	694561898	shares
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-2365000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	66005000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-5823000	usd
	us-gaap	Net Income Loss NetIncomeLoss	55093000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment	-1069000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment	-455000	usd
	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment	-1001000	usd
	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment	23373000	usd
CY2024Q3	EVFM	Reclassification Adjustment Related To Debt Extinguishment ReclassificationAdjustmentRelatedToDebtExtinguishment	143000	usd
CY2023Q3	EVFM	Reclassification Adjustment Related To Debt Extinguishment ReclassificationAdjustmentRelatedToDebtExtinguishment	-73187000	usd
	EVFM	Reclassification Adjustment Related To Debt Extinguishment ReclassificationAdjustmentRelatedToDebtExtinguishment	143000	usd
	EVFM	Reclassification Adjustment Related To Debt Extinguishment ReclassificationAdjustmentRelatedToDebtExtinguishment	-73187000	usd
CY2024Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3291000	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7637000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6681000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	5279000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-66510000	usd
CY2024Q1	EVFM	Stock Issued During Period Value Common Stock Upon Cash Exercise Of Warrants StockIssuedDuringPeriodValueCommonStockUponCashExerciseOfWarrants	15000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	89000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	35000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	237000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment	324000	usd
CY2024Q1	EVFM	Adjustments To Additional Paid In Capital Value Accumulated Deficit And Retained Earnings AdjustmentsToAdditionalPaidInCapitalValueAccumulatedDeficitAndRetainedEarnings	-47000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-4809000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-70666000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	68000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	16000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	219000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment	-256000	usd
CY2024Q2	EVFM	Adjustments To Additional Paid In Capital Value Accumulated Deficit And Retained Earnings AdjustmentsToAdditionalPaidInCapitalValueAccumulatedDeficitAndRetainedEarnings	-47000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	1351000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-69315000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-69315000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	11000	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	203000	usd
CY2024Q3	us-gaap	Extinguishment Of Debt Amount ExtinguishmentOfDebtAmount	143000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment	-1069000	usd
CY2024Q3	EVFM	Adjustments To Additional Paid In Capital Value Accumulated Deficit And Retained Earnings AdjustmentsToAdditionalPaidInCapitalValueAccumulatedDeficitAndRetainedEarnings	-5000	usd
CY2024Q3	EVFM	Stock Issued During Period Value Issuance Of Series F1 Shares To Aditxt Related Party StockIssuedDuringPeriodValueIssuanceOfSeriesF1SharesToAditxtRelatedParty	1193000	usd
CY2024Q3	EVFM	Adjustments To Additional Paid In Capital Allocation Of Reinstatement Proceeds Related Party AdjustmentsToAdditionalPaidInCapitalAllocationOfReinstatementProceedsRelatedParty	316000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-2365000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	-70888000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	-70888000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-71800000	usd
CY2023Q1	EVFM	Stock Issued During Period Value Common Stock Upon Cash Exercise Of Warrants StockIssuedDuringPeriodValueCommonStockUponCashExerciseOfWarrants	67000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	180000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	1629000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment	15460000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	417000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2354000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-56401000	usd
CY2023Q2	EVFM	Stock Issued During Period Value Common Stock Upon Cash Exercise Of Warrants StockIssuedDuringPeriodValueCommonStockUponCashExerciseOfWarrants	101000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	6000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	53000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	499000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	268000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment	8368000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-8558000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-55664000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-55664000	usd
CY2023Q3	EVFM	Stock Issued During Period Value Common Stock Upon Cash Exercise Of Warrants StockIssuedDuringPeriodValueCommonStockUponCashExerciseOfWarrants	14000	usd
CY2023Q3	EVFM	Issuance Of Series E1 Convertible And Redeemable Preferred Stock Upon Exchange Of Notes IssuanceOfSeriesE1ConvertibleAndRedeemablePreferredStockUponExchangeOfNotes	-1800000	usd
CY2023Q3	EVFM	Issuance Of Series E1 Convertible And Redeemable Preferred Stock Upon Exchange Of Notes IssuanceOfSeriesE1ConvertibleAndRedeemablePreferredStockUponExchangeOfNotes	-1800000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	3563000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	4904000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	258000	usd
CY2023Q3	us-gaap	Extinguishment Of Debt Amount ExtinguishmentOfDebtAmount	73187000	usd
CY2023Q3	EVFM	Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustments OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustments	-452000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	66005000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	66005000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-56359000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-56359000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-5823000	usd
	us-gaap	Net Income Loss NetIncomeLoss	55093000	usd
	us-gaap	Gain Loss On Sale Of Derivatives GainLossOnSaleOfDerivatives	-3300000	usd
	us-gaap	Gain Loss On Sale Of Derivatives GainLossOnSaleOfDerivatives	-5286000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	977000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	75337000	usd
	EVFM	Change In Fair Value Of Financial Instruments ChangeInFairValueOfFinancialInstruments	4896000	usd
	EVFM	Change In Fair Value Of Financial Instruments ChangeInFairValueOfFinancialInstruments	1539000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	1505000	usd
	EVFM	Loss On Contingent Liability LossOnContingentLiability	840000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	659000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	943000	usd
	us-gaap	Depreciation Depreciation	25000	usd
	us-gaap	Depreciation Depreciation	455000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	301000	usd
	us-gaap	Interest Expense InterestExpense	1673000	usd
	us-gaap	Interest Expense InterestExpense	1702000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	69000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1259000	usd
	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	466000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-11000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-1858000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-345000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	5196000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-234000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1348000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-195000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-3231000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-211000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1215000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	2234000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1632000	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	613000	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-355000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-69000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1432000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1477000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8798000	usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	509000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	14000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-523000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4000	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	174000	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	397000	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	5262000	usd
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	1260000	usd
	EVFM	Proceeds From Reinstatement Of Merger Agreement Related Party ProceedsFromReinstatementOfMergerAgreementRelatedParty	1000000	usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	515000	usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1000000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2142000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4436000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	142000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-4366000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	580000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4776000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	722000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	410000	usd
	EVFM	Exchange Of Convertible Notes To Series E1 Convertible Preferred Stock ExchangeOfConvertibleNotesToSeriesE1ConvertiblePreferredStock	1800000	usd
	EVFM	Borrowings Under Term Notes Included In Prepaid And Other Current Assets BorrowingsUnderTermNotesIncludedInPrepaidAndOtherCurrentAssets	375000	usd
	EVFM	Net Change In Contingent Consideration Liabilities NetChangeInContingentConsiderationLiabilities	13743000	usd
	EVFM	Allocation Of Reinstatement Proceeds Related Party AllocationOfReinstatementProceedsRelatedParty	316000	usd
	EVFM	Issuance Of Common Stock Upon Exercise Of Purchase Rights IssuanceOfCommonStockUponExerciseOfPurchaseRights	168000	usd
	EVFM	Issuance Of Common Stock Upon Exercise Of Purchase Rights IssuanceOfCommonStockUponExerciseOfPurchaseRights	186000	usd
	EVFM	Series E1 Shares Dividends SeriesE1SharesDividends	99000	usd
	EVFM	Rightofuse Assets Obtained For Lease Liabilities Fleet Lease Renewals RightofuseAssetsObtainedForLeaseLiabilitiesFleetLeaseRenewals	90000	usd
	EVFM	Acquisition Related Amounts Included In Accounts Payable And Accrued Expenses AcquisitionRelatedAmountsIncludedInAccountsPayableAndAccruedExpenses	70000	usd
	EVFM	Issuance Of Common Stock Upon Conversion Of Notes IssuanceOfCommonStockUponConversionOfNotes	51000	usd
	EVFM	Issuance Of Common Stock Upon Exercise Of Warrants IssuanceOfCommonStockUponExerciseOfWarrants	15000	usd
	EVFM	Purchases Of Property And Equipment Included In Accounts Payable And Accrued Expenses PurchasesOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses	78000	usd
CY2024Q3	EVFM	Working Capital Surplus Deficit WorkingCapitalSurplusDeficit	-67700000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-894600000	usd
CY2022Q4	us-gaap	Share Price SharePrice	0.01
CY2022Q4	us-gaap	Share Price SharePrice	0.01
CY2024Q3	us-gaap	Share Price SharePrice	0.01
CY2022Q4	us-gaap	Share Price SharePrice	0.01
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_842_eus-gaap--UseOfEstimates_zSe78um26ka7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_864_zJKZqZPKZTq5">Use of Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and the notes thereto.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant estimates affecting amounts reported or disclosed in the condensed consolidated financial statements include, but are not limited to: the assumptions used in measuring the revenue gross-to-net variable consideration items; the trade accounts receivable credit loss reserve estimate; the assumptions used in estimating the fair value of convertible notes, preferred stock, warrants, purchase rights issued, asset acquisition intangible asset, and contingent liabilities; the assumptions used in the valuation of inventory; the useful lives of property and equipment; the recoverability of long-lived assets; and the valuation of deferred tax assets. These assumptions are more fully described in <a href="#n_003">Note 3 – Revenue</a>, <a href="#n_004">Note 4 – Debt</a>, <a href="#n_006">Note 6 - Fair Value of Financial Instruments</a>, <a href="#n_007">Note 7 - Commitments and Contingencies</a>, and <a href="#n_009">Note 9 - Stock-based Compensation</a>. The Company bases its estimates on historical experience and market-specific or other relevant assumptions that it believes to be reasonable under the circumstances and adjusts when facts and circumstances dictate. The estimates are the basis for making judgments about the carrying values of assets, liabilities and recorded expenses that are not readily apparent from other sources. As future events and their effects cannot be determined with precision, actual results may materially differ from those estimates or assumptions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84D_eus-gaap--ConcentrationRiskCreditRisk_zVRrgJUDRiI7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_865_zcy59ivtcd37">Concentrations of Credit Risk</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and restricted cash. Deposits in the Company’s checking, time deposit and investment accounts are maintained in federally insured financial institutions and are subject to federally insured limits or limits set by Securities Investor Protection Corporation. The Company invests in funds through a major U.S. bank and is exposed to credit risk in the event of default to the extent of amounts recorded on the condensed consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has not experienced any losses in such accounts and believes it is not exposed to significant concentrations of credit risk on its cash, cash equivalents and restricted cash balances on amounts in excess of federally insured limits due to the financial position of the depository institutions in which these deposits are held.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is also subject to credit risk related to its trade accounts receivable from product sales. Its customers are located in the U.S. and consist of wholesale distributors, retail pharmacies, and mail-order specialty pharmacies. The Company extends credit to its customers in the normal course of business after evaluating their overall financial condition and evaluates the collectability of its accounts receivable by periodically reviewing the age of the receivables, the financial condition of its customers, and its past collection experience. Historically, the Company has not experienced any credit losses. As of September 30, 2024, based on the evaluation of these factors the Company did not record a reserve for expected credit loss.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Products are distributed primarily through three major distributors and mail-order pharmacies, who receive service fees calculated as a percentage of the gross sales, and a fee-per-unit shipped, respectively. These entities are not obligated to purchase any set number of units and distribute products on demand as orders are received.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the three and nine months ended September 30, 2024, the Company’s three largest customers combined made up approximately <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240701__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--ThreeLargestCustomersCombinedMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zZeN9qUQJtd9" title="Concentration risk percentage">80</span>% and <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--ThreeLargestCustomersCombinedMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z4vnSnf2R5wh" title="Concentration risk percentage">79</span>% of its gross product sales, respectively. For the three and nine months ended September 30, 2023, the Company’s three largest customers combined made up approximately <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--ThreeLargestCustomersCombinedMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zcZV3ORs5WO4" title="Concentration risk percentage">86</span>% and <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--ThreeLargestCustomersCombinedMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zdnuuykKwoRi" title="Concentration risk percentage">85</span>% of its gross product sales, respectively. As of September 30, 2024 and December 31, 2023, the Company’s three largest customers combined made up <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--ThreeLargestCustomersCombinedMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zRWzb8aDwYxe" title="Concentration risk percentage">90</span>% and <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--ThreeLargestCustomersCombinedMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zEP2iFuCtBcc" title="Concentration risk percentage">87</span>%, respectively, of its trade accounts receivable balance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p>
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	25000000.0	usd
CY2024Q3	us-gaap	Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount	100000	usd
	us-gaap	Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount	100000	usd
CY2024Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5786905201	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5786905201	shares
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	66005000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	55093000	usd
CY2023Q3	EVFM	Purchase Rights Change In Fair Value PurchaseRightsChangeInFairValue	4904000	usd
	EVFM	Purchase Rights Change In Fair Value PurchaseRightsChangeInFairValue	5008000	usd
CY2023Q3	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	361000	usd
	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	1064000	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	71270000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	61165000	usd
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4236477	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2524302	shares
CY2023Q3	EVFM	Weighted Average Shares Used To Compute Net Loss Attributable To Common Stockholder Diluted WeightedAverageSharesUsedToComputeNetLossAttributableToCommonStockholderDiluted	731128443	shares
	EVFM	Weighted Average Shares Used To Compute Net Loss Attributable To Common Stockholder Diluted WeightedAverageSharesUsedToComputeNetLossAttributableToCommonStockholderDiluted	694561899	shares
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.10
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.09
CY2024Q3	EVFM	Product Revenue Variable Consideration Liability Current ProductRevenueVariableConsiderationLiabilityCurrent	200000	usd
CY2023Q4	EVFM	Product Revenue Variable Consideration Liability Current ProductRevenueVariableConsiderationLiabilityCurrent	300000	usd
CY2024Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	4500000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	3200000	usd
CY2021Q4	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	50000000	usd
CY2023Q2	EVFM	Milestone Method Revenue Recognized MilestoneMethodRevenueRecognized	100000000.0	usd
CY2024Q3	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	0.0154
CY2023Q1	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	92700000	usd
CY2023Q2	EVFM	Milestone Method Revenue Recognized MilestoneMethodRevenueRecognized	100000000.0	usd
CY2023Q3	EVFM	Cumulative Net Sales CumulativeNetSales	100000000	usd
CY2023Q3	EVFM	Accrued Interest Agreement Percentage AccruedInterestAgreementPercentage	0.10	pure
CY2023Q3	us-gaap	Interest Revenue Expense Net InterestRevenueExpenseNet	1000000.0	usd
CY2023Q4	us-gaap	Interest Revenue Expense Net InterestRevenueExpenseNet	1000000.0	usd
CY2023Q4	us-gaap	Interest Paid Net InterestPaidNet	500000	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	75300000	usd
CY2023	EVFM	Revalued Amount Extinguishment Of Debt Amount RevaluedAmountExtinguishmentOfDebtAmount	73200000	usd
CY2024Q3	us-gaap	Repayments Of Debt RepaymentsOfDebt	100000	usd
	us-gaap	Repayments Of Debt RepaymentsOfDebt	400000	usd
CY2024Q3	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	556000	usd
CY2023Q3	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	516000	usd
	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	1637000	usd
	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	1520000	usd
CY2023Q3	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	51000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	28000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	179000	usd
CY2024Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	556000	usd
CY2023Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	567000	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	1665000	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	1699000	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	615861541	shares
CY2024Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	423000	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	520000	usd
CY2024Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	863000	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	386000	usd
CY2024Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	177000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	791000	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	1463000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	1697000	usd
CY2024Q3	us-gaap	Inventory Adjustments InventoryAdjustments	300000	usd
CY2023Q4	us-gaap	Inventory Adjustments InventoryAdjustments	300000	usd
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	1300000	usd
CY2024Q3	us-gaap	Prepaid Insurance PrepaidInsurance	627000	usd
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	777000	usd
CY2024Q3	EVFM	Prepaid Research And Development Expenses PrepaidResearchAndDevelopmentExpenses	23000	usd
CY2023Q4	EVFM	Prepaid Research And Development Expenses PrepaidResearchAndDevelopmentExpenses	13000	usd
CY2024Q3	us-gaap	Deposits Assets Current DepositsAssetsCurrent	202000	usd
CY2023Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	76000	usd
CY2024Q3	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	147000	usd
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	329000	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	999000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1195000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1876000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2389000	usd
CY2024Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	695000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1186000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1181000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1203000	usd
CY2023Q3	us-gaap	Depreciation Depreciation	500000	usd
	us-gaap	Depreciation Depreciation	500000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	301000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	14021000	usd
CY2024Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	300000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	300000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	300000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	1300000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	1300000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	1300000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	1300000	usd
CY2024Q3	EVFM	Finite Lived Intangible Assets Amortization Expense After Year Four FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour	1300000	usd
CY2024Q3	EVFM	Accrued Clinical Studies Current AccruedClinicalStudiesCurrent	2498000	usd
CY2023Q4	EVFM	Accrued Clinical Studies Current AccruedClinicalStudiesCurrent	2498000	usd
CY2024Q3	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	1723000	usd
CY2023Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	1146000	usd
CY2024Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	903000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	583000	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5124000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4227000	usd
CY2024Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	162000	usd
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	1926000	usd
CY2023Q3	EVFM	Net Revenues NetRevenues	10000000.0	usd
CY2023Q3	EVFM	Cumulative Net Sales CumulativeNetSales	100000000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P11Y
	EVFM	Long Term Purchase Commitment Expected Amount LongTermPurchaseCommitmentExpectedAmount	3500000	usd
CY2024Q3	us-gaap	Long Term Purchase Commitment Amount LongTermPurchaseCommitmentAmount	100000	usd
	us-gaap	Long Term Purchase Commitment Amount LongTermPurchaseCommitmentAmount	100000	usd
CY2024Q3	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	200000	usd
CY2024Q3	us-gaap	Purchase Obligation Due In Second Year PurchaseObligationDueInSecondYear	1300000	usd
CY2024Q3	us-gaap	Purchase Obligation Due In Third Year PurchaseObligationDueInThirdYear	1900000	usd
	us-gaap	Payments For Royalties PaymentsForRoyalties	0	usd
CY2024Q3	us-gaap	Payments For Royalties PaymentsForRoyalties	0	usd
	EVFM	Number Of Leased Vehicles NumberOfLeasedVehicles	19	integer
CY2019Q4	EVFM	Office Square Footage OfficeSquareFootage	24474	sqft
CY2020Q2	EVFM	Office Square Footage OfficeSquareFootage	8816	sqft
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3300000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4200000	usd
CY2023Q2	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	200000	usd
CY2022Q2	EVFM	Lessee Operating Sublease Rentable Area LesseeOperatingSubleaseRentableArea	16637	sqft
CY2022Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	100000	usd
CY2022Q2	us-gaap	Operating Leases Of Lessor Contingent Rentals Basis Spread On Variable Rate OperatingLeasesOfLessorContingentRentalsBasisSpreadOnVariableRate	0.035	pure
CY2024Q3	us-gaap	Sublease Income SubleaseIncome	300000	usd
	us-gaap	Sublease Income SubleaseIncome	300000	usd
CY2024Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	43000	usd
CY2023Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	58000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	145000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	764000	usd
CY2024Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y11M19D
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y9M
CY2024Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.12	pure
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.12	pure
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	39000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	86000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	8000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	133000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	7000	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	126000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	218000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	1470000	usd
CY2024Q3	us-gaap	Unrecorded Unconditional Purchase Obligation Purchases UnrecordedUnconditionalPurchaseObligationPurchases	800000	usd
	us-gaap	Unrecorded Unconditional Purchase Obligation Purchases UnrecordedUnconditionalPurchaseObligationPurchases	1000000.0	usd
CY2023Q3	us-gaap	Unrecorded Unconditional Purchase Obligation Purchases UnrecordedUnconditionalPurchaseObligationPurchases	0	usd
	us-gaap	Unrecorded Unconditional Purchase Obligation Purchases UnrecordedUnconditionalPurchaseObligationPurchases	0	usd
CY2023Q3	us-gaap	Accounts Payable Trade Current And Noncurrent AccountsPayableTradeCurrentAndNoncurrent	1500000	usd
CY2024Q3	EVFM	Accounts Payable Trade90 Days Past Due Or More Percent AccountsPayableTrade90DaysPastDueOrMorePercent	0.87	pure
CY2022Q3	EVFM	Contingent Liabilities Current ContingentLiabilitiesCurrent	800000	usd
CY2022Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	894194	shares
CY2023Q4	us-gaap	Common Stock Other Shares Outstanding CommonStockOtherSharesOutstanding	9972074	shares
CY2024Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2.42
CY2024Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	20807539	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q3	us-gaap	Excess Stock Shares Authorized ExcessStockSharesAuthorized	2300	shares
CY2023Q3	EVFM	Debt Instrument Redemption Premium In Event Of Default DebtInstrumentRedemptionPremiumInEventOfDefault	0.25	pure
CY2023	us-gaap	Adjustments To Additional Paid In Capital Increase In Carrying Amount Of Redeemable Preferred Stock AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock	1800000	usd
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3000000000	shares
CY2024Q3	EVFM	Common Stock Reserved Upon Exercise Of Stock Options Outstanding CommonStockReservedUponExerciseOfStockOptionsOutstanding	3747	shares
CY2024Q3	EVFM	Common Stock Reserved Upon Exercise Of Common Stock Warrants CommonStockReservedUponExerciseOfCommonStockWarrants	10598201	shares
CY2024Q3	EVFM	Common Stock Capital Share Reserved For Future Issuances CommonStockCapitalShareReservedForFutureIssuances	741490642	shares
CY2024Q3	us-gaap	Convertible Preferred Stock Shares Reserved For Future Issuance ConvertiblePreferredStockSharesReservedForFutureIssuance	158598174	shares
CY2024Q3	us-gaap	Preferred Stock Capital Shares Reserved For Future Issuance PreferredStockCapitalSharesReservedForFutureIssuance	40991761	shares
CY2024Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	951689432	shares
CY2024Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	203000	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	258000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	659000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	943000	usd
CY2024Q3	us-gaap	Stock Issued During Period Shares Conversion Of Units StockIssuedDuringPeriodSharesConversionOfUnits	2727668	shares
CY2024Q3	us-gaap	Preferred Stock Convertible Conversion Price PreferredStockConvertibleConversionPrice	0.04

Files In Submission

Name	View Source	Status
0001493152-24-046060-index-headers.html	Edgar Link	pending
0001493152-24-046060-index.html	Edgar Link	pending
0001493152-24-046060.txt	Edgar Link	pending
0001493152-24-046060-xbrl.zip	Edgar Link	pending
evfm-20240930.xsd	Edgar Link	pending
ex10-14.htm	Edgar Link	pending
ex10-15.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
evfm-20240930_cal.xml	Edgar Link	unprocessable
evfm-20240930_def.xml	Edgar Link	unprocessable
evfm-20240930_lab.xml	Edgar Link	unprocessable
evfm-20240930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EVFM
Evofem Biosciences, Inc. Stock $evfm

2024 Q4 Form 10-Q Financial Statement

#000149315224046060 Filed on November 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EVFM Evofem Biosciences, Inc. Stock $evfm

2024 Q4 Form 10-Q Financial Statement

#000149315224046060 Filed on November 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EVFM
Evofem Biosciences, Inc. Stock $evfm